The role of antibody concentration and avidity in antiviral protection.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Science

• Publication date

  1997-06-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/SCIENCE.276.5321.2024PMID 9197261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monovalent single‐chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection

  1996cited by this paper
• Mapping of the dominant neutralizing antigenic site of a virus using infected cells.

  1996cited by this paper
• T helper cell‐independent neutralizing B cell response against vesicular stomatitis virus: Role of antigen patterns in B cell induction?

  1995cited by this paper
• Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice

  1995cited by this paper
• Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity.

  1995cited by this paper
• Kinetic and affinity limits on antibodies produced during immune responses.

  1995cited by this paper
• Functional role of type I and type II interferons in antiviral defense.

  1994cited by this paper
• How many specific B cells are needed to protect against a virus?

  1994cited by this paper
• Protective anti-reovirus monoclonal antibodies and their effects on viral pathogenesis

  1993cited by this paper
• Mechanisms of rabies virus neutralization.

  1993cited by this paper
• The influence of antigen organization on B cell responsiveness.

  1993cited by this paper
• Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses

  1993cited by this paper
• Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system.

  1992cited by this paper
• Antibody-mediated clearance of alphavirus infection from neurons.

  1991cited by this paper
• Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection

  1991cited by this paper
• Murine infection by vesicular stomatitis virus: initial characterization of the H-2d system

  1991cited by this paper
• Affinity maturation of antibodies.

  1991cited by this paper
• Kinetic maturation of an immune response

  1991cited by this paper
• High-affinity antibody induced by immunization with a synthetic peptide is associated with protection of cattle against foot-and-mouth disease.

  1991cited by this paper
• The protecton: the unit of humoral immunity selected by evolution.

  1990cited by this paper
• The Protection: The Unit of Humoral Immunity Selected by Evolution

  1990cited by this paper
• Mapping of antigenic sites on the bovine ephemeral fever virus glycoprotein using monoclonal antibodies.

  1990cited by this paper
• The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus.

  1988cited by this paper
• Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo

  1984cited by this paper
• The effects of idiotype on the ability of IgG1 antiphosphorylcholine antibodies to protect mice from fatal infection with Streptococcus pneumoniae

  1984cited by this paper
• The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies.

  1982cited by this paper
• VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE.

  1964cited by this paper

• Synergies in Self‐Assembly—From Supramolecular Polymers to Defined Hierarchical Superstructures

  2025cites this paper
• Development of high affinity antibodies to Plasmodium falciparum merozoite and sporozoite antigens during infancy and adulthood

  2025cites this paper
• Molecular ingredients of an immunogen for long-lasting IgG

  2025cites this paper
• Detection and Validation of Influenza Virus Hemagglutinin Specific, Cross‐Reactive, and Heteroclitic B Cells Induced by a Combination Vaccine Adjuvant

  2025cites this paper
• Superior Potency of Synthetic Virus-like Structures in Vaccine-Induced Antibody Responses Compared to Qβ Bacteriophage Virus-like Particles

  2025cites this paper
• Influence of adjuvant type and route of administration on the immunogenicity of Leishmania-derived tick-borne encephalitis virus-like particles - a recombinant vaccine candidate.

  2024cites this paper
• Description of a non-competitive ELISA based on time course analysis of ligand binding at saturation, and a direct method for calculating the affinity of monoclonal antibodies.

  2024cites this paper
• Mechanical control of antigen detection and discrimination by T and B cell receptors

  2024cites this paper
• Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity

  2024cites this paper
• RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques

  2023cites this paper
• Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity

  2023cites this paper
• Antigen spacing on protein nanoparticles influences antibody responses to vaccination

  2023cites this paper
• Determination of Binding Affinity of Antibodies to HIV-1 Recombinant Envelope Glycoproteins, Pseudoviruses, Infectious Molecular Clones, and Cell-Expressed Trimeric gp160 Using Microscale Thermophoresis

  2023influential citation
• Characterization of B‐cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS‐CoV‐2 infection

  2023cites this paper
• Antigen spacing on protein nanoparticles influences antibody responses to vaccination

  2023cites this paper
• Characterization and immunogenicity of a novel chimeric hepatitis B core-virus like particles (cVLPs) carrying rotavirus VP8*protein in mice model.

  2023cites this paper
• Monoclonal antibody on-rate constant determined from time-course data of ligand binding by capture ELISA: Evaluation of eight data analysis methods.

  2022cites this paper
• Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development

  2022cites this paper
• RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer

  2022cites this paper
• Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection

  2022cites this paper
• Mucosal plasma cells are required to protect the upper airway and brain from infection.

  2022cites this paper
• HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial

  2022cites this paper
• Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for treatment of intraocular neovascular disorders

  2021cites this paper
• Development of a competitive inhibition kinetic ELISA to determine the inhibition constant (Ki) of monoclonal antibodies.

  2021cites this paper
• Profiling the Quality and Quantity of Naturally Induced Antibody Responses Against Pfs230 and Pfs48/45 Among Non-Febrile Children Living in Southern Ghana: A Longitudinal Study

  2021cites this paper
• Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients

  2021cites this paper
• Progress and challenges in mass spectrometry-based analysis of antibody repertoires.

  2021cites this paper
• Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses

  2021cites this paper
• The Shaping of a B Cell Pool Maximally Responsive to Infections.

  2021cites this paper
• Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

  2021cites this paper
• Zika Virus Envelope Domain III Recombinant Protein Delivered With Saponin-Based Nanoadjuvant From Quillaja brasiliensis Enhances Anti-Zika Immune Responses, Including Neutralizing Antibodies and Splenocyte Proliferation

  2021cites this paper
• Genetic Basis of Antigenic Variation of SAT3 Foot-And-Mouth Disease Viruses in Southern Africa

  2020cites this paper
• Shaping Polyclonal Responses via Antigen-Mediated Antibody Interference

  2020cites this paper
• Impact of vaccination on measles, mumps, and rubella antibody titers in Japanese healthcare workers: An observational study

  2020cites this paper
• The role of hepatitis B surface antibodies in HBV infection, disease and clearance

  2020cites this paper
• Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination

  2020cites this paper
• Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only

  2020cites this paper
• Cross-reactivity reduced dengue virus 2 vaccine has no cross-protection against heterotypic dengue viruses

  2020cites this paper
• Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.

  2019cites this paper
• Multiple Variables at the Leukocyte Cell Surface Impact Fc γ Receptor-Dependent Mechanisms

  2019cites this paper
• Characterization of antibody response in patients with acute and chronic chikungunya virus disease.

  2019cites this paper
• Defective circulating and intrahepatic B cells in chronic HBV

  2019cites this paper
• Augmenting adaptive immunity: progress and challenges in the quantitative engineering and analysis of adaptive immune receptor repertoires

  2019cites this paper
• Mucosal antibody quantity but not avidity predicts likelihood of Salmonella infection in red-eared slider turtles (Trachemys scripta).

  2019cites this paper
• Cross-reactivity reduced dengue virus serotype 2 vaccine does not confer cross-protection against other serotypes of dengue viruses

  2018cites this paper
• A dengue monovalent vaccine with novel structure provides cross-protection against four serotypes of dengue virus

  2018cites this paper
• Alternatives for the serological assessment of foot-and-mouth disease vaccine immunity in buffaloes (Bubalus bubalis)

  2018cites this paper
• Hyaluronic Acid Conjugates of TLR7/8 Agonists for Targeted Delivery to Secondary Lymphoid Tissue.

  2018cites this paper
• What if protective immunity is antigen—driven and not due to so‐called “memory” B and T cells?

  2018cites this paper
• An epitope-resurfaced virus-like particle can induce broad neutralizing antibody against four serotypes of dengue virus

  2018cites this paper
• Application of Serological Tests to Assess the Efficacy of Foot-and-Mouth Disease Vaccination in Dairy Cattle with or without Viral Leucosis

  2018cites this paper
• Envelope glycoproteins of vesiculoviruses : characteristics of antibody interactions and immunogenicity

  2018cites this paper
• IgA Function in Relation to the Intestinal Microbiota.

  2018cites this paper
• Factors influencing the induction of high affinity antibodies to Plasmodium falciparum merozoite antigens and how affinity changes over time

  2018cites this paper
• Foot and mouth disease vaccine strain selection: current approaches and future perspectives

  2018cites this paper
• Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development

  2018cites this paper
• Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes

  2017cites this paper
• Green Tea Catechin-Inactivated Viral Vaccine Platform

  2017influential citation
• Biomaterial strategies for generating therapeutic immune responses

  2017cites this paper
• A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects

  2017cites this paper
• Molecular Design of a Minimal Peptide Nanoparticle.

  2017cites this paper
• Major findings and recent advances in virus-like particle (VLP)-based vaccines.

  2017cites this paper
• Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda

  2017cites this paper
• Live baculovirus acts as a strong B and T cell adjuvant for monomeric and oligomeric protein antigens.

  2017cites this paper
• Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation

  2017cites this paper
• Classification of self-assembling protein nanoparticle architectures for applications in vaccine design

  2017cites this paper
• Substrate stiffness governs the initiation of B cell activation by the concerted signaling of PKCβ and focal adhesion kinase

  2017influential citation
• This information is current as Effects Triggering TLR-and RLH-Dependent Virus-Specific Vaccine Responses by Locally A New RNA-Based Adjuvant Enhances

  2017cites this paper
• HPV vaccines: how many doses are needed for protection?

  2016cites this paper
• Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™

  2016cites this paper
• Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes

  2016cites this paper
• Immunological memory: lessons from the past and a look to the future

  2016cites this paper
• The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants

  2015cites this paper
• Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site

  2015cites this paper
• eview olecular properties of human IgG subclasses and their implications or designing therapeutic monoclonal antibodies against infectious iseases

  2015cites this paper
• Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.

  2015cites this paper
• Protective effect of a germline, IL‐17‐neutralizing antibody in murine models of autoimmune inflammatory disease

  2015cites this paper
• Exploration of Toll-like Receptor 7 and 8 Agonists as Potential Vaccine Adjuvants

  2015cites this paper
• 164 – Vesicular Stomatitis Virus and Related Vesiculoviruses

  2015cites this paper
• Characterization of humoral immune responses to two subunit malaria vaccine candidates in humans

  2015cites this paper
• TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity

  2015cites this paper
• Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01E in Young Children

  2014cites this paper
• Quantitative assessment of the robustness of next-generation sequencing of antibody variable gene repertoires from immunized mice

  2014cites this paper
• On plasma cell longevity or brevity

  2014influential citation
• Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses

  2014cites this paper
• Correlation between Dengue-Specific Neutralizing Antibodies and Serum Avidity in Primary and Secondary Dengue Virus 3 Natural Infections in Humans

  2013cites this paper
• The link between antibodies to OxLDL and natural protection against pneumococci depends on DH gene conservation

  2013cites this paper
• Reduced varicella-zoster-virus (VZV)-specific lymphocytes and IgG antibody avidity in solid organ transplant recipients.

  2013cites this paper
• Noncovalent mass spectrometry for the characterization of antibody/antigen complexes.

  2013cites this paper
• How specific is too specific? B‐cell responses to viral infections reveal the importance of breadth over depth

  2013cites this paper
• Characterization of IgG Effector Responses to Mouse Cytomegalovirus in Susceptible and Resistant Mouse Strains

  2013cites this paper
• Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

  2013cites this paper
• Division of labor during primary humoral immunity

  2013cites this paper
• An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies.

  2013cites this paper
• Virus-Like Particles as Efficient Delivery Platform to Induce a Potent Immune Response

  2012cites this paper
• Functional Flexibility of Intestinal IgA – Broadening the Fine Line

  2012cites this paper
• TARTIŞILAN ADJUVAN: SKUALEN

  2012cites this paper
• Innovation in Vaccinology

  2012cites this paper
• The role of antibody affinity in mediating protection against autoimmune inflammatory diseases

  2012cites this paper
• B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity.

  2012influential citation